Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
NextGen (NXGN) Reinforces Its Robust Solutions Portfolio
by Zacks Equity Research
NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific
Veeva (VEEV) Vault Applications Get Adopted by GenesisCare
by Zacks Equity Research
Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.
CVS Health (CVS) 2021 Selling Season Strong, LTC Arm Suffers
by Zacks Equity Research
Since the start of the pandemic, CVS Health (CVS) is seeing more than 40% of all specialty orders being placed digitally.
Boston Scientific's (BSX) SCS Systems Receives FDA's Nod
by Zacks Equity Research
Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
by Zacks Equity Research
Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Abbott's (ABT) Libre 2 Cleared in Canada, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) next-generation FreeStyle Libre 2 system aims to provide a better quality of life to diabetics in Canada at the same affordable price of the current FreeStyle Libre system.
Cooper Companies (COO) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter earnings reflect weak segmental performance. However, it exceeds expectation as it witnesses faster-than-anticipated recovery.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.
Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout
by Zacks Equity Research
This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.
BD (BDX) to Boost Pre-Fillable Syringe-Manufacturing Capacity
by Zacks Equity Research
BD (BDX) is set to improve its pre-fillable syringe-manufacturing ability with its expansion and upgrade plans.
Hologic's (HOLX) New AI Technology Now Available Post FDA Nod
by Zacks Equity Research
Hologic's (HOLX) latest 3D CAD solution is expected to aid in early detection of breast cancer along with prioritizing the most concerning patient cases.
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription Service and Professional Service segments deliver an impressive performance in Q3.
Patterson Companies (PDCO) Q2 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2021 results benefit from strong segmental performance.
AMN Healthcare (AMN) Boosts Service Portfolio With New Offering
by Zacks Equity Research
AMN Healthcare's (AMN) new pledge to provide support minority-owned businesses, thereby helping them to thrive.
Hill-Rom (HRC) FLC Growth Continues, Surgical Arm Stays Dull
by Zacks Equity Research
Within Front Line Care (FLC), Hill-Rom (HRC) registers growth in vital signs monitoring, blood pressure and thermometry as well as the completion of the U.S. stockpile order for noninvasive ventilators.
Boston Scientific (BSX) to Divest BTG's Non-MedTech Arm
by Zacks Equity Research
BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.
Align Technology (ALGN) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Align Technology (ALGN) is optimistic about maintaining a robust product portfolio along with strength in its international business.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Baxter (BAX) Announces Site Expansion to Improve Patient Care
by Zacks Equity Research
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.